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Introduction
Parkinson’s disease (PD) is a chronic degenerative disease 
of the nervous system that affects about 1% of people over 
the age of 65; after Alzheimer’s disease, it is the second 
most common disease in this group. This disease is 
associated with the loss of dopaminergic neurons in the 
dense portion of the substantial nigra in the midbrain 
and corpus striatum, which results in motor function 
impairments and, in progressive cases, leads to cognitive 
impairments. 
Previously, the focus was on studying the diseases and 
their mortality rate, while in recent years, researchers 
have increasingly focused on studying patients’ quality of 
life (QoL) and health and functional status.1, 2
In PD, the patients’ QoL can improve by identifying 
factors that reduce QoL (e.g., poor sleep quality, chronic 
fatigue, and positive interventions).3 Common treatments 
for PD include medication and deep brain stimulation 
(DBS). However, these therapies only reduce the 
patient’s motor symptoms; that is to say, over time and 
by the disease progression, their effects also decrease and 
they may no longer be able to prevent the progressive 
degeneration of dopaminergic neurons. Long-term use 
of these drugs also causes some complications, including 
dyskinesia.4 In the treatment process of this complex 
disease, complementary therapies are also proposed 
to repair degenerations and reduce symptoms. In this 
regard, some studies have shown the medical effects of 
the turmeric plant. They have proved the anti-oxidant, 
anti-inflammatory, and neuronal protective properties of 
curcumin.5 Modification of dopamine and acetylcholine 
receptors in the brain of mice with PD and Alzheimer’s 
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Abstract
Background: Considering the evidence indicating the neuronal protective effects of curcumin in 
previous studies, this double-blind, randomized, placebo-controlled, and parallel-group trial was 
aimed at exploring the possible nanomicelle curcumin (SinaCurcumin®, nano-micellar soft gel)-
mediated impact on sleep, fatigue, and quality of life (QoL) in patients with Parkinson’s disease (PD). 
Methods: A sample of 50 PD patients were recruited and randomly divided into experimental (25) 
and control groups (25). Sleep quality, fatigue, and QoL were assessed based on the Pittsburgh Sleep 
Quality Index (PSQI), Fatigue Severity Scale (FSS), and the Parkinson’s Disease Questionnaire–39 
(PDQ-39), respectively, at the beginning and the end of the study. The groups were treated for three 
months by 80 mg of nano-micellar soft gel twice a day. 
Results: Nanomicelle curcumin significantly increased sleep quality and QoL compared with 
placebo (P values = 0.0001 and 0.0002, respectively) in PD patients. This significant difference has 
not influenced by the duration of the disease, the severity of disease progression (Hoehn & Yahr 
scale), and the cumulative dose of levodopa. This supplement did not have a significant effect on the 
fatigue severity of patients compared to placebo. 
Conclusion: It has proposed that the nanomicelle curcumin can be used to improve sleep quality 
and QoL in PD patients.
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life.
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diseases is also one of the beneficial effects attributed to 
curcumin. The positive effects on cognitive functions 
and depression are also other features associated with 
curcumin.6-12
One of the important limitations of curcumin is its low 
bioavailability, which is due to its low solubility in the 
aquatic environment of the body.1 Alzheimer’s clinical 
studies have also shown no significant effects of curcumin, 
which is due, in part, to its low bioavailability and 
solubility.11,14 The solution to this deficiency, curcumin 
supplied in other ways, such as in combination with other 
drugs and the nanoform administration of curcumin, 
which, on the one hand, increases the bioavailability 
of this substance and, on the other hand, increases its 
efficacy.15-17 Therefore, this study was set to examine the 
clinical effects of nanomicelle curcumin on sleep quality, 
fatigue, and QoL in PD patients.
Methods
Patients
A double-blind, randomized, placebo-controlled, and 
parallel-group trial was conducted to determine the 
efficacy of nanomicelle curcumin (SinaCurcumin®. 
Nano-Micellar Soft gel; Eksir Nano-Sina Minoo Co., 
Iran) compared with placebo on sleep quality, fatigue, and 
QoL in PD patients. A total of 50 patients who referred 
to the Neurology clinic at Vali-e-Asr hospital in Zanjan 
were selected and randomly divided into experimental 
and control groups. Inclusion criteria were adapted to 
include patients with idiopathic PD (MDS-PD criteria); 
having at least elementary education; filling up the 
consent form and Unified Parkinson’s Disease Rating 
Scale (Hoehn & Yahr) (I-III); not changing the drug and 
supplement therapy since the month prior to the start 
of the experiment; being 35 years old and over; having 
no report of allergy to turmeric and other foods and 
supplements; and having PD history of less than 10 years. 
Individuals with abnormal renal and liver function tests, 
cognitive disorders, epilepsy, stroke, and other cerebral 
diseases, severe disability caused by dementia or other 
diseases, and gastric disorders, gastroesophageal reflux 
disease, and gastric ulcers excluded from the study.
Study design
Restricted randomization was used applying the random 
allocation rule. Therefore, a sample of 50 participants was 
selected and randomly assigned into two groups (there 
were 25 participants in group A and 25 in group B). 
One group received the drug, and the other one received 
placebo, but none of the patients knew which group 
received the drug or placebo. Moreover, all physicians, 
nurses, statistician, and the person responsible for drafting 
the manuscript did not know anything about the drug or 
placebo. SAS software used for randomization. Moreover, 
sequentially numbered, opaque, sealed envelopes used for 
allocation concealment.
In the experimental group, PD patients received one 
80 mg soft gelatin capsule of nanomicelle Sina-Curcumin 
after breakfast and one after dinner for 3 months. The drug 
contained curcumin (diferuloylmethane), a polyphenol 
from the group of diarylheptanoids. The most active part of 
the root of the turmeric plant belongs to the ginger family, 
which together with the other 2 main uurcuminoids, 
demethoxycurcumin and bisdemethoxycurcumin, makes 
up about 3% to 5% of the turmeric plant. In the control 
group, PD patients received one 80 mg soft gelatin capsule 
of placebo nanomicelle Sina-Curcumin after breakfast 
and one after dinner for 3 months; the placebo did not 
contain any active ingredient. Moreover, the packaging 
and dosage forms were kept identical.
Outcome Measures
The data collected via clinical examinations, interviews, 
and questionnaires before and after the administration 
of the supplement. Primary data included age, gender, 
duration of the disease (time elapsed since diagnosis), 
the severity of the disease, the type of prescribed drug, 
and the cumulative dose of levodopa. Measurement 
tools used were Hoehn & Yahr scale for stage of disease 
progression, Sleep quality based on the Pittsburgh Sleep 
Quality Index (PSQI),18 Fatigue based on Fatigue Severity 
Scale (FSS),19 and QoL based on the Parkinson’s Disease 
Questionnaire–39 (PDQ-39)20 at the beginning and end of 
the study. The validity and reliability of the Persian version 
of these questionnaires were previously approved.19, 21  
Statistical Analyses 
Kolmogorov-Smirnov and Shapiro-Wilks tests were used 
to check for normality of the distribution. All parameters 
obtained at the beginning and end of the study in the 
nanomicelle curcumin and placebo groups were compared 
using paired-samples t test. Mixed-effects regression 
models have also used to compare the changes in outcome 
variables before and after intervention with and without 
possible confounders. All the two-sided P values <0.05 




Demographic and Clinical Data
Of the 135 registered patients, 85 were ineligible, not 
meeting the inclusion criteria. Therefore, 25 patients in 
the nanomicelle curcumin arm and 25 patients in the 
placebo arm were eligible (Figure 1). Fifty patients with 
PD, including 13 women (26%) and 37 men (74%), 
participated in the study. There were no lost-to-follow-up 
cases in this clinical trial. The mean age of the patients 
was 65.44±10.48. The disease progression stage based on 
the Hoehn and Yahr scale was 24% in 12 patients (stage I), 
42% in 21 patients (stage II), and 34% in 17 patients (stage 
III). Out of 49 patients, 22 (44%) took levodopa (L-3,4-
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dihydroxyphenylalanine-LD), 5 (10%) took dopamine 
agonist-DA, and 22 (44%) took LD and DA. One patient 
(2%) received no medication due to the mildness of the 
symptoms. The levodopa dose was 100 to 499 mg for 20 
patients (40%) and 500 to 1000 mg for 24 patients (48%). 
The disease duration varied from 1 to 10 years. It was 
five years or less in 35 (70%) patients and more than five 
years in 15 (30%) patients. Demographic and clinical data 
presented in Table 1. 
Outcome Measures
The distribution of data in all groups was normal (P > 
0.05). The mean values of sleep quality scores based on 
PSQI in the placebo group before and after the intervention 
were 9.49 and 7.64, respectively, and in the experimental 
group were 12.20 and 6.04, respectively. Based on paired-
samples t test, the difference between the mean scores of 
the 2 groups was significant (P = 0.0001) (Table 2). This 
significant relationship has not influenced by the duration 
of the disease. The severity of the disease, the cumulative 
dose of levodopa, since the P value for these variables was 
higher than 0.05. However, the relationship has influenced 
the type of prescribed drug (P = 0.009).
Mean values of FSS in the placebo group before and after 
intervention were 38.92 and 40.60, respectively, and in the 
experimental group were 44.40 and 40.16, respectively. 
Based on the paired-samples t test, the difference between 
the mean scores of the two groups was not significant 
(P = 0.42) (Table 2).
The mean scores of QoL based on PDQ-39 in the 
placebo group before and after the intervention were 
36.40 and 34.92, respectively, and in the experimental 
group were 51.24 and 31.88, respectively. Based on 
the paired-samples t test, the difference in mean scores 
between the two groups was significant (P = 0.0002) 
(Table 2). This significant relationship has not influenced 
by the duration of the disease, severity, and the cumulative 
dose of levodopa since the P value for these variables was 
higher than 0.05. However, the relationship influenced by 
the type of prescribed drug (P = 0.02).
Discussion
Nanomicelle curcumin significantly increased the 
sleep quality and QoL in patients with PD compared 
to the placebo group (P values were 0.0001 and 0.0002, 
respectively). This correlation has not influenced by the 
duration of the disease, the severity of the disease, and 
the cumulative dose of levodopa; nevertheless, the type 
of prescribed drug-affected it. This supplement did not 
have a significant effect on the fatigue severity of patients 
compared with the placebo. 
In a randomized polysomnography double-blind study, 
controlled with placebo, Pierantozzi et al investigated 
the effectiveness of rotigotine versus placebo regarding 
PSG parameters in advanced PD patients. For all 
participants, polysomnography, Parkinson’s Disease 
Sleep Scale (PDSS), PSQI, and motor skill assessment 
questionnaires administered early in the morning. Forty-
two patients with PD (stages 2 and 3 of H&Y) and sleep 
disorders randomly divided into 2 groups. Rotigotine 
Figure 1. Flowchart of the Study.
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significantly improved sleep efficiency and reduced early 
morning awakening and sleep latency rates compared to 
the placebo. Also, mean changes in rapid eye movement 
sleep rate in the rotigotine group were significantly higher 
than those in the placebo group. Improvement of PSG 
parameters was associated with improvement of PDSS 
symptoms, and PSQI was associated with improvement 
of early-morning motor symptoms.22 Although in the 
study conducted by Pierantozzi et al rotigotine was used 
as a dopamine receptor agonist from the non-ergoline 
drug category, its effectiveness was comparable to that of 
nanomicelle curcumin supplement in our study.
Chronic fatigue syndrome, infection, and oxidative 
stress are interrelated in epidemiological studies. 
However, data demonstrating scientific validation of 
epidemiological claims regarding the effectiveness of food 
supplements on chronic fatigue syndrome are lacking. 
Gupta et al examined the effect of curcumin in a mouse 
model of immunologically induced fatigue and used 
pure lipopolysaccharide and Brucella abortus antigens as 
immunogens. Chronic fatigue syndrome was evaluated 
based on a chronic periodic stress test for 19 days during 
immobility times as a fatigue marker. Mice challenged 
with lipopolysaccharide or Brucella abortus for 19 days; 
they showed a significant increase in immobility and 
hyperalgesia on day 19, and their TNF-alpha serum levels 
increased. Simultaneous treatment with curcumin resulted 
in a significant reduction in immobility and hyperalgesia. 
Oxidative stress and TNF-alpha decreased. These findings 
strongly suggest a significant increase in oxidative stress 
during immunological activation and confirm that 
curcumin can be a valuable option in the treatment of 
chronic fatigue syndrome.23 Huang et al evaluated the 
effect of a curcumin supplement on physiological fatigue 
and physical performance in rats. The rats were divided 
into 4 groups and received oral administration of 0, 12.3, 
24.6, or 61.5 mL/kg/d (180 μg/mL) curcumin supplement 
for four weeks. By examining forelimb grip strength, levels 
of physical fatigue-associated biomarkers, serum lactate, 
ammonia, blood urea nitrogen, glucose markers, and 
tissue damage markers such as aspartate transaminase, 
alanine transaminase, and creatine kinase  the anti-fatigue 
performance evaluated. Curcumin supplement increased 
grip strength dose-dependently and significantly reduced 
the amount of lactate, ammonia, blood urea nitrogen, 
aspartate aminotransferase, alanine aminotransferase, 
and creatine kinase after a physical challenge. Muscle 
glycogen content has significantly increased.2 Moreover, 
Ledda et al evaluated the effectiveness of Merami® 
(CurcuminPhytosome®) supplement in transient primary 
renal microalbuminuria. Patients received three capsules 
per day containing 300 mg of curcumin in a form with a 
high absorption level.
In comparison with the control group, albuminuria 
improved within four weeks, and fatigue has significantly 
decreased or disappeared.25 Although these studies 
indicate the effect of curcumin on the treatment of 
chronic fatigue syndrome, this supplement did not have a 
significant effect on the fatigue severity of PD patients in 
the present study. This difference in outcome may explain 
by differences in the type of study design and type of 
diseases.
Pharmaceutical delivery systems that can provide non-
bound curcuminoids are essential because the absorption 
of bioactive and penetrable forms plays a critical role in 
its effectiveness. Pandaren Sudheeran et al examined the 
immunity, antioxidant, and bioavailability effectiveness of 
CurQfen (curcumagalactomannoside (CGM)), a natural 
formulation of curcumin with fenugreek diet fiber. In 
this randomized, double-blind trial with a control group 
receiving placebo, 60 participants with anxiety and fatigue 
related to occupational stress were randomly assigned to 
Table 1. Demographic and Clinical Data
Nanomicelle Curcumin Group (n=25) Placebo Group (n=25)
(Mean ± SD) (Mean ± SD)
Age 67.80±10.14 63.08±10.47
The duration of the disease (y) 4.36±2.37 4.68±3.11
The cumulative dose of levodopa (mg/d) 495.65±286.79 526.25±249.27
Table 2. Comparison of Mean Scores of Sleep Quality Based on PSQI, Fatigue Severity Based on FSS, and QoL Based on PDQ-39 in 2 Selected Groups in PD 
Patients Using T test for 2 Paired Samples.
Nanomicelle Curcumin Group (N=25) Placebo Group (N=25)
Before Intervention After Intervention Before Intervention After Intervention
(Mean ± SD) (Mean ± SD) (Mean ± SD) (Mean ± SD)
PSQI 12.20±7.79 6.04±4.42a 9.40±7.58 7.64±6.62
FSS 44.40±17.77 40.16±14.90 38.92±17.83 40.60±14.44
PDQ-39 51.24±31.31 31.88±19.36b 36.40±24.75 34.92±23.09
a P = 0.0001; b P = 0.0002
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receive CGM, standard curcumin, and placebo for 30 
days (500 mg twice daily). The participants examined the 
Medical Outcomes Study Short Form (SF)-36, stress scale, 
and Beck anxiety scores. A significant improvement in 
QoL (P < 0.05) and significant reductions regarding stress 
(P < 0.001), anxiety (P < 0.001), and fatigue (P < 0.001) 
observed in the CGM group as compared with the group 
receiving standard curcumin. Improvement of QoL was 
associated with a significant increase in antioxidant 
markers and reduction of lipid peroxidation.26 In this 
study, 500 mg of CurQfen was used twice a day for a 
month, while in our study, 80 mg of nanomicelle curcumin 
(the consumption dose reduced 6 times) was used twice a 
day for three months. Although the studied groups were 
different, nanomicelle curcumin significantly increased 
QoL in PD patients. 
Major depression is a common and chronic disease that 
decreases QoL and increases mortality risk. In a clinical 
meta-analysis study, Al-Karawi et al examined the role 
of curcumin in patients with major depressive disorders. 
Six clinical trials selected according to inclusion criteria. 
In general, oral administration of curcumin showed 
a significant reduction in depression symptoms. The 
subgroup analyses showed that curcumin had the most 
significant effect on the middle-aged population in 
long-term use and higher doses. The result showed that 
curcumin reduces the symptoms of depression in patients 
with depression.6 Although the study conducted by Al-
Karawi et al was on non-Parkinson groups, their findings 
were consistent with the results of the current work in 
terms of the effectiveness of curcumin on QoL. 
In sum, we propose that Nanomicelle curcumin may 
improve sleep quality and QoL in PD patients. The 
present study has some strengths. It is a double-blind, 
randomized, placebo-controlled, and parallel-group trial. 
We used nanomicelle curcumin that has a high absorption 
rate and is stable in the acidic environment of the stomach 
for 6 hours. The effect of curcumin on sleep, fatigue, and 
QoL in PD patients evaluated for the first time based on 
PDQ-39, PSQI, and FSS questionnaires.
Moreover, other variables such as duration of the disease, 
severity of the disease, cumulative dose of levodopa, and 
the type of prescribed drug have also controlled. The 
limitation of the study may be a relatively low number of 
participants in each group. On the other hand, the study 
had a short-term follow-up, and therefore, conclusions 
are reasonable only for that period of follow-up. 
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